Now what?














The Ingrezza reps are trying! Manage care drives everything! Anybody who thinks otherwise has there head in the sand. We have no real clinical medical differentiation that a provider can medically justify.
All the cookies and cakes and candy we deliver can’t change these facts.
 


And now the shut down of a clinical trial coupled with the stock hit a few weeks ago. Paying for all these added people to our once lean- mean sales force will be a recipe for disaster once the next quarterly earnings come out. Loosing share weekly to freaking Teva and Austedo won't pay the bills for all these new re-treads we are hiring. Just damn, can we hold off on all these territory overlaps!
 


And now the shut down of a clinical trial coupled with the stock hit a few weeks ago. Paying for all these added people to our once lean- mean sales force will be a recipe for disaster once the next quarterly earnings come out. Loosing share weekly to freaking Teva and Austedo won't pay the bills for all these new re-treads we are hiring. Just damn, can we hold off on all these territory overlaps!
These KAS roles are a complete waste. Our executive leadership has become deaf and blind. This will waste our time and piss off our customers. What a waste of resources.
 








On another note, what do we do if our company vehicle just got flooded with storm surge from Milton? Oh wait, that was my previous pharma job where we actually had a company vehicle that didn't cost us a dime to drive. I guess I'll be paying a higher car insurance premium that my weak-ass car allowance won't cover.
 


On another note, what do we do if our company vehicle just got flooded with storm surge from Milton? Oh wait, that was my previous pharma job where we actually had a company vehicle that didn't cost us a dime to drive. I guess I'll be paying a higher car insurance premium that my weak-ass car allowance won't cover.
Or you could go get another job and save us your whining
 




Or you could go get another job and save us your whining
It's going to be interesting on our next earnings call when the shareholders question Austedo's dominance in market share takeover. It was just 10 months ago or at the end of last year where our glorious leader told the street that we would never relinquish that position in the VMAT2 class.
 


It's going to be interesting on our next earnings call when the shareholders question Austedo's dominance in market share takeover. It was just 10 months ago or at the end of last year where our glorious leader told the street that we would never relinquish that position in the VMAT2 class.
Ya, most of my scripts are patient assistance now. Do we have a plan? I feel like the company is giving up.
 









Write your reply...